ADVANCED SOLID TUMORS

This early-phase study tested an experimental drug called SHR-A1811 in 396 adults with advanced solid tumors that have a specific marker (HER2). The main goals were to check safety and how the drug moves through the body. Researchers also looked for signs that the drug might shri…

This early-stage study tested a new drug called ZGGS15 in 22 adults with advanced solid tumors that no longer responded to standard treatments. The main goals were to check the drug's safety, find the best dose, and look for any side effects. Researchers also watched for signs th…

This study tested a new treatment called Anti-ALPP CAR-T cells in 5 people with advanced solid tumors that had not responded to standard therapies. The treatment uses a patient's own immune cells, modified to attack a protein (ALPP) found on many cancer cells. The main goals were…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced solid tumors (including breast, ovarian, stomach, colorectal, brain, bile duct, and pancreatic cancers) that had stopped responding to standard treatments. The goal was to see …

This early-stage trial tested a new oral drug called ASC61 in 18 adults with advanced solid tumors that had stopped responding to standard treatments or had no standard options. The goal was to check the drug's safety, find the right dose, and see if it could shrink tumors. ASC61…

This study tested a new drug called ensartinib (X-396) in 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The main goal was to find the safest dose and see if the drug could shrink tumors. Results helped guide further research …

This early-phase study tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed. The main goals were to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the body and wh…

This early-stage study tested a new drug, KL340399, injected directly into tumors of 6 people with advanced solid cancers that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The stu…

This study tested a new drug called MK-1200 in 13 people with advanced stomach, esophageal, bile duct, or pancreatic cancers that had stopped responding to other treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The trial was completed, but res…

This early-stage study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the highest safe dose, and see how the drug moves through the body. This is not a cure bu…

This study looked at 161 people with advanced solid tumors (like lung, bladder, skin, and kidney cancers) who had already been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. Half stopped treatment, and half continued. The goal was to see if st…